Repare Therapeutics Inc. (RPTX)

CA — Healthcare Sector
Peers: ALXO  BMEA  ACRV  IMUX  PMVP  DTIL  UNCY  CAMP  ATYR  GUTS 

Automate Your Wheel Strategy on RPTX

With Tiblio's Option Bot, you can configure your own wheel strategy including RPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RPTX
  • Rev/Share 0.0058
  • Book/Share 2.6795
  • PB 0.7949
  • Debt/Equity 0.003
  • CurrentRatio 10.7079
  • ROIC -0.6856

 

  • MktCap 91544471.0
  • FreeCF/Share -1.6327
  • PFCF -1.305
  • PE -1.2675
  • Debt/Assets 0.0027
  • DivYield 0
  • ROE -0.5756

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights
RPTX, SEE
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Read More
image for news Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
RPTX
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Repare Therapeutics Inc. (NASDAQ: RPTX ) related to its sale to XenoTherapeutics, Inc. Upon closing of the proposed transaction, it is estimated that each Repare shareholder will receive a cash payment of $1.82 per share, plus one …

Read More
image for news $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
RPTX
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Negative

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.

Read More
image for news Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

About Repare Therapeutics Inc. (RPTX)

  • IPO Date 2020-06-19
  • Website https://www.reparerx.com
  • Industry Biotechnology
  • CEO Steve Forte
  • Employees 129

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.